Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $10.00 at Citigroup

Intellia Therapeutics (NASDAQ:NTLA) had its target price cut by Citigroup from $14.00 to $10.00 in a research report released on Friday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other research analysts have also recently issued reports on NTLA. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Wolfe Research raised Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price on the stock in a report on Monday, April 21st. Chardan Capital restated a “buy” rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a research report on Friday. The Goldman Sachs Group reaffirmed a “sell” rating and set a $9.00 target price on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Oppenheimer lowered their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $36.47.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $8.12 on Friday. The stock has a 50-day moving average of $8.13 and a two-hundred day moving average of $11.06. The stock has a market cap of $841.09 million, a P/E ratio of -1.49 and a beta of 2.33. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts’ expectations of $11.39 million. During the same quarter in the prior year, the company earned ($1.12) EPS. Intellia Therapeutics’s quarterly revenue was down 42.6% on a year-over-year basis. Analysts predict that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc increased its stake in Intellia Therapeutics by 2.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after acquiring an additional 1,100 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Intellia Therapeutics by 14.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock valued at $157,000 after purchasing an additional 1,582 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Intellia Therapeutics by 6.1% during the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after purchasing an additional 1,615 shares during the period. E Fund Management Co. Ltd. increased its position in shares of Intellia Therapeutics by 10.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock worth $210,000 after purchasing an additional 1,634 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in Intellia Therapeutics by 47.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company’s stock valued at $61,000 after buying an additional 1,692 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.